These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 8978998

  • 1. Mycophenolate mofetil in kidney transplantation.
    Lui SL, Halloran PF.
    Curr Opin Nephrol Hypertens; 1996 Nov; 5(6):508-13. PubMed ID: 8978998
    [Abstract] [Full Text] [Related]

  • 2. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 3. Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection.
    Simmons WD, Rayhill SC, Sollinger HW.
    Drug Saf; 1997 Aug 15; 17(2):75-92. PubMed ID: 9285199
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation.
    Fulton B, Markham A.
    Drugs; 1996 Feb 15; 51(2):278-98. PubMed ID: 8808168
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The cost effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplant. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sullivan SD, Garrison LP, Best JH.
    J Am Soc Nephrol; 1997 Oct 15; 8(10):1592-8. PubMed ID: 9335389
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M, Carl S.
    J Urol; 1998 Jan 15; 159(1):28-33. PubMed ID: 9400430
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mycophenolate mofetil.
    Sievers TM, Rossi SJ, Ghobrial RM, Arriola E, Nishimura P, Kawano M, Holt CD.
    Pharmacotherapy; 1997 Jan 15; 17(6):1178-97. PubMed ID: 9399601
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
    Machnicki G, Ricci JF, Brennan DC, Schnitzler MA.
    Pharmacoeconomics; 2008 Jan 15; 26(11):951-67. PubMed ID: 18850764
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM, Lloveras J, Fernández-Crespo P, Mir M, Iñigo V, Manresa JM, Masramón J.
    Transplant Proc; 1999 Sep 15; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.